索磷布韦/维帕他韦在丙型肝炎病毒感染孕妇中的药代动力学、安全性与疗效
纳入11例慢性HCV感染孕妇,妊娠23至25周起每日给予索磷布韦/维帕他韦12周。维帕他韦AUC与非妊娠历史数据相似,索磷布韦AUC高38%,GS-331007低38%;完成治疗者分娩时HCV RNA均检测不到,有数据者均治愈(n=9),婴儿无HCV感染(n=8)。
要点
- 维帕他韦在孕妇中AUC与非妊娠历史数据相似
- 索磷布韦AUC较非妊娠高38%,GS-331007低38%
- 完成治疗者分娩时HCV RNA均检测不到,有数据者均治愈
核心结论
- 索磷布韦/维帕他韦暴露在妊娠期与非妊娠期无临床差异,支持进一步评估产前索磷布韦/维帕他韦治疗。
研究设计与样本
- 孕妇慢性HCV感染者在妊娠23至25周入组,每日给予索磷布韦/维帕他韦12周,于第3、6、9周进行药代动力学访视。
- 测定血浆维帕他韦、索磷布韦及GS-331007,以及外周血单核细胞和干血斑中索磷布韦活性代谢物007-TP,与非妊娠历史数据比较。
- 评估母亲不良事件、分娩结局、治疗结束后12周持续病毒学应答、婴儿不良事件及HCV围产期传播。
- 14例筛查,11例入组;1例因妊娠剧吐加重停药。
主要发现
- 维帕他韦AUC与非妊娠历史数据相似,索磷布韦AUC较非妊娠高38%,GS-331007 AUC较非妊娠低38%。
- 外周血单核细胞中007-TP浓度与 nonpregnant 相当或更高,干血斑中007-TP较非妊娠低约50%。
- 完成治疗的10例参与者分娩时HCV RNA均检测不到。
- 分娩后2例失访,其中1例经临床护理获得HCV RNA数据;有数据者均治愈(n=9),婴儿无HCV感染(n=8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 1例因妊娠剧吐加重停药。
- 分娩后2例失访。
- 婴儿HCV感染评估仅8例有数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of hepatitis C virus (HCV) during pregnancy can cure maternal HCV and prevent perinatal HCV transmission. The primary objective was to compare the pharmacokinetics (PK) of sofosbuvir (SOF)/velpatasvir (VEL) in pregnant versus nonpregnant people. METHODS: Pregnant people with chronic HCV infection were enrolled between 23 and 25 weeks' gestation and were provided SOF/VEL daily for 12 weeks. PK visits were performed at 3, 6, and 9 weeks. VEL, SOF, and GS-331007 (the inactive metabolite of SOF) in plasma and the SOF active metabolite (007-TP) in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBSs) were measured and compared to historical data in nonpregnant people. Maternal adverse events, delivery outcomes, the sustained virologic response 12 weeks after therapy, infant adverse events, and HCV perinatal transmission were assessed. RESULTS: Fourteen participants were screened, and 11 enrolled. One participant discontinued treatment due to worsening of hyperemesis. VEL area under the curve (AUC) was similar to historic data in nonpregnant people, but the AUCs of SOF and GS-331007 were 38% higher and 38% lower, respectively. Concentrations of 007-TP in PBMCs were comparable or higher, whereas 007-TP in DBSs was approximately 50% lower in pregnant versus nonpregnant people. All 10 participants who completed treatment had undetectable HCV RNA at delivery. Two participants were lost to follow-up after delivery, but 1 had an HCV RNA through clinical care. All participants with data were cured (n = 9) and none of the infants acquired HCV (n = 8). CONCLUSIONS: SOF/VEL exposures were not clinically different in pregnancy and support further evaluation of antenatal SOF/VEL treatment.
引用
- Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025. PMID: 39688397. doi:10.1093/cid/ciae595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。